Headache and Migraine

As a 2026 SEQUINS Hall of Fame honoree, George Howard, DrPH, commented on decades of stroke disparities research, the impact of the REGARDS study, and why future efforts must focus more directly on upstream risk factors.

As a 2026 SEQUINS Hall of Fame honoree, Gretchen L. Birbeck, MD, MPH, reflected on her decades-long work advancing equity in global neurologic care and improving epilepsy outcomes in resource-limited settings.

As a 2026 SEQUINS Hall of Fame honoree, Edwin Trevathan, MD, MPH, reflects on global pediatric neurology, community-based care delivery, and the ongoing effort to reduce neurologic health inequities worldwide.

Phase 2/3 LIBRA trial design evaluates basimglurant, an mGluR5 modulator, using a randomized withdrawal approach to assess durability of pain control and safety in adults with trigeminal neuralgia.

A recently presented analysis at AAN 2026 reported comparable safety and tolerability between atogepant and erenumab, with atogepant demonstrating a greater likelihood of early response at 1 month in adults with migraine.

Phase 3 data presented at AAN 2026 show fremanezumab significantly reduces monthly migraine days in pediatric episodic migraine but not chronic migraine.

Single-dose adjunctive dexamethasone did not significantly lower 48-hour relapse rates or improve functional outcomes in children and adolescents treated for acute migraine in the emergency department.

A data-driven slideshow for National Public Health Week highlights the global burden of neurologic diseases, featuring key statistics on prevalence, disability, and workforce gaps across major conditions.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 13, 2026.

A recently published position statement from the American Headache Society recommends annual screening for migraine in girls and women, highlighting the potential role of tools like the ID Migraine screener to improve identification.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 6, 2026.

The associate professor of neurology at Mayo Clinic provided a breakdown of the real-world eptinezumab data from INFUSE and its implications for early, robust migraine intervention after CGRP failure.

Real-world INFUSE results show IV eptinezumab boosts good days and cuts monthly headache days for hard-to-treat migraine patients.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 27, 2026.

In this Q&A, migraine expert Deena Kuruvilla, MD, FAAN, provided clinical context on the phase 4 COMPEL trial testing onabotulinumtoxinA as a preventive treatment of chronic migraine in diverse racial groups.

Off-label rimegepant was associated with patient-reported acute migraine improvement and no new safety signals in a small retrospective review of adolescent patients.

Bruce Ovbiagele, MD, MSc, MAS, MBA, founding president of the Society for Equity Neuroscience (SEQUINS) reflects on Black History Month, SEQUINS initiatives, and the policy and guideline reforms needed to advance brain health equity in 2026 and beyond.

New data suggest that prophylactic treatment with anti-calcitonin gene-related peptide monoclonal antibodies may be associated with improvements in sleep quality and daytime sleepiness among patients with migraine.

Fremanezumab, a humanized monoclonal antibody that selectively targets calcitonin gene–related peptide, demonstrated efficacy in children and adolescents with episodic migraine in full data release.

ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.

A Phase 1 study in healthy lactating women found that a single 10‑mg dose of zavegepant nasal spray was generally safe, well tolerated, and resulted in minimal infant exposure through breast milk.

Follow NeurologyLive's conference journey in 2026, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

Explore anticipated FDA decisions on groundbreaking neurology drugs in 2026, shaping treatment options for various neurologic conditions.

As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews on the latest advances and use of artificial intelligence in neurology care.

As part of NeurologyLive®'s Year in Review 2025, we've compiled some of the top trending migraine trials.